Immunic Develops Pipeline of Oral Therapies for Chronic Inflammatory and Autoimmune Diseases

2 min read | September 27, 2024 05:50 AM PDT | By Team Kalkine Media

Google News:

Immunic Develops Pipeline of Oral Therapies for Chronic Inflammatory and Autoimmune Diseases — Image source: Shutterstock

Recent News

Oracle's AI Push Gains Ground Across Critical Services

Why is Marathon Petroleum (NYSE:MPC) moving with S&P 500 Energy?

Why AbbVie (NYSE:ABBV) Gains in S&P 500 Index Biopharma Push?

Why FactSet Research Systems Anchors Index Stability Gains Now?

Make Kalkine Media
My Trusted Source

Highlights

Immunic Inc (NASDAQ:IMUX) is advancing its lead asset, vidofludimus calcium, currently in Phase 3 trials for multiple sclerosis, with promising data presented at the ECTRIMS Congress.
The drug has shown potential to reduce neurofilament light chain levels, suggesting it may slow disease progression and alleviate fatigue in MS patients.
Immunic is also exploring vidofludimus calcium for post-COVID syndrome, with the first patient enrolled in a Phase 2 trial sponsored by Goethe University Frankfurt.

Article

Immunic Inc (NASDAQ:IMUX) is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead candidate, vidofludimus calcium (IMU-838), is currently in Phase 3 clinical trials for multiple sclerosis (MS) and has demonstrated therapeutic activity in earlier Phase 2 trials, particularly in patients with relapsing-remitting MS and moderate-to-severe ulcerative colitis. This compound selectively inhibits activated immune cells, showcasing anti-inflammatory, anti-viral, and neuroprotective properties.

On September 18, 2024, Immunic announced key findings regarding vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Data from the Phase 2 CALLIPER trial revealed that the drug consistently reduced neurofilament light chain (NfL) levels, indicating its potential to slow disease progression across various MS subtypes. Additionally, it may help alleviate fatigue in MS patients by preventing reactivation of the Epstein-Barr virus (EBV), which is associated with increased fatigue levels. Preclinical studies have also suggested neuroprotective effects linked to Nurr1 activation, which could enhance neuronal survival.

In a significant expansion of its research scope, Immunic has initiated an investigator-sponsored Phase 2 trial evaluating vidofludimus calcium for post-COVID syndrome, with the first patient enrolled in early September. The RAPID_REVIVE study is backed by funding from the German Federal Ministry of Education and Research, showcasing the compound’s versatility in addressing diverse health challenges.

Dr. Andreas Muehler, Immunic’s Chief Medical Officer, highlighted the company’s strong presence at the ECTRIMS Congress, marking a milestone with its own booth for the first time. The event allowed Immunic to showcase data from four posters, including insights from the CALLIPER trial and the drug's potential effects on MS-related fatigue and antiviral properties.

With critical milestones ahead, including the CALLIPER trial readout scheduled for April 2025, Immunic Inc continues to solidify its role in advancing treatments for MS and exploring new therapeutic avenues for patients with unmet medical needs.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.